Managed  ||| S:0 E:8 ||| VBN
care  ||| S:8 E:13 ||| NN
&  ||| S:13 E:15 ||| CC
medical  ||| S:15 E:23 ||| JJ
oncology ||| S:23 E:31 ||| NN
:  ||| S:31 E:33 ||| :
the  ||| S:33 E:37 ||| DT
focus  ||| S:37 E:43 ||| NN
is  ||| S:43 E:46 ||| VBZ
on  ||| S:46 E:49 ||| IN
value  ||| S:49 E:55 ||| NN
A  ||| S:55 E:57 ||| DT
previous  ||| S:57 E:66 ||| JJ
NCCN  ||| S:66 E:71 ||| NNP
Oncology  ||| S:71 E:80 ||| NNP
Insights  ||| S:80 E:89 ||| NNPS
Reportdescribed  ||| S:89 E:105 ||| NNP
the  ||| S:105 E:109 ||| DT
factors  ||| S:109 E:117 ||| NNS
making  ||| S:117 E:124 ||| VBG
cancer  ||| S:124 E:131 ||| NN
care  ||| S:131 E:136 ||| NN
a  ||| S:136 E:138 ||| DT
priority  ||| S:138 E:147 ||| NN
for  ||| S:147 E:151 ||| IN
managed  ||| S:151 E:159 ||| JJ
care  ||| S:159 E:164 ||| NN
organizations  ||| S:164 E:178 ||| NNS
( ||| S:178 E:179 ||| -LRB-
MCOs ||| S:179 E:183 ||| NNP
)  ||| S:183 E:185 ||| -RRB-
and  ||| S:185 E:189 ||| CC
emerging  ||| S:189 E:198 ||| VBG
trends  ||| S:198 E:205 ||| NNS
in  ||| S:205 E:208 ||| IN
managing  ||| S:208 E:217 ||| VBG
costs  ||| S:217 E:223 ||| NNS
of  ||| S:223 E:226 ||| IN
cancer  ||| S:226 E:233 ||| NN
care ||| S:233 E:237 ||| NN
.  ||| S:237 E:239 ||| .
To  ||| S:239 E:242 ||| TO
better  ||| S:242 E:249 ||| RB
understand  ||| S:249 E:260 ||| VB
the  ||| S:260 E:264 ||| DT
concerns  ||| S:264 E:273 ||| NNS
of  ||| S:273 E:276 ||| IN
MCOs  ||| S:276 E:281 ||| JJ
and  ||| S:281 E:285 ||| CC
how  ||| S:285 E:289 ||| WRB
they  ||| S:289 E:294 ||| PRP
are  ||| S:294 E:298 ||| VBP
addressing  ||| S:298 E:309 ||| VBG
cancer  ||| S:309 E:316 ||| NN
costs  ||| S:316 E:322 ||| NNS
and  ||| S:322 E:326 ||| CC
quality ||| S:326 E:333 ||| NN
,  ||| S:333 E:335 ||| ,
NCCN  ||| S:335 E:340 ||| NNP
interviewed  ||| S:340 E:352 ||| VBD
senior  ||| S:352 E:359 ||| JJ
physician  ||| S:359 E:369 ||| NN
executives  ||| S:369 E:380 ||| NNS
from  ||| S:380 E:385 ||| IN
the  ||| S:385 E:389 ||| DT
3  ||| S:389 E:391 ||| CD
largest  ||| S:391 E:399 ||| JJS
payors  ||| S:399 E:406 ||| NN
in  ||| S:406 E:409 ||| IN
the  ||| S:409 E:413 ||| DT
United  ||| S:413 E:420 ||| NNP
States ||| S:420 E:426 ||| NNPS
.  ||| S:426 E:428 ||| .
The  ||| S:428 E:432 ||| DT
interviews  ||| S:432 E:443 ||| NNS
provided  ||| S:443 E:452 ||| VBD
insights  ||| S:452 E:461 ||| VBN
into  ||| S:461 E:466 ||| IN
how  ||| S:466 E:470 ||| WRB
these  ||| S:470 E:476 ||| DT
companies  ||| S:476 E:486 ||| NNS
managed  ||| S:486 E:494 ||| VBD
oncology  ||| S:494 E:503 ||| JJ
care ||| S:503 E:507 ||| NN
,  ||| S:507 E:509 ||| ,
with  ||| S:509 E:514 ||| IN
an  ||| S:514 E:517 ||| DT
emphasis  ||| S:517 E:526 ||| NN
on  ||| S:526 E:529 ||| IN
drugs  ||| S:529 E:535 ||| NNS
and  ||| S:535 E:539 ||| CC
biologics ||| S:539 E:548 ||| NN
.  ||| S:548 E:550 ||| .
As  ||| S:550 E:553 ||| IN
a  ||| S:553 E:555 ||| DT
follow-up  ||| S:555 E:565 ||| JJ
to  ||| S:565 E:568 ||| TO
the  ||| S:568 E:572 ||| DT
previous  ||| S:572 E:581 ||| JJ
report ||| S:581 E:587 ||| NN
,  ||| S:587 E:589 ||| ,
NCCN  ||| S:589 E:594 ||| NNP
conducted  ||| S:594 E:604 ||| VBD
additional  ||| S:604 E:615 ||| JJ
interviews  ||| S:615 E:626 ||| NNS
with  ||| S:626 E:631 ||| IN
medical  ||| S:631 E:639 ||| JJ
executives  ||| S:639 E:650 ||| NNS
from  ||| S:650 E:655 ||| IN
10  ||| S:655 E:658 ||| CD
MCOs  ||| S:658 E:663 ||| NN
between  ||| S:663 E:671 ||| IN
February  ||| S:671 E:680 ||| NNP
and  ||| S:680 E:684 ||| CC
April  ||| S:684 E:690 ||| NNP
2010 ||| S:690 E:694 ||| CD
.  ||| S:694 E:696 ||| .
The  ||| S:696 E:700 ||| DT
organizations  ||| S:700 E:714 ||| NNS
represented  ||| S:714 E:726 ||| VBD
in  ||| S:726 E:729 ||| IN
these  ||| S:729 E:735 ||| DT
interviews  ||| S:735 E:746 ||| NNS
were  ||| S:746 E:751 ||| VBD
Aetna ||| S:751 E:756 ||| NNP
,  ||| S:756 E:758 ||| ,
BlueCross  ||| S:758 E:768 ||| JJ
BlueShield  ||| S:768 E:779 ||| NN
of  ||| S:779 E:782 ||| IN
Minnesota ||| S:782 E:791 ||| NNP
,  ||| S:791 E:793 ||| ,
BlueShield  ||| S:793 E:804 ||| JJ
of  ||| S:804 E:807 ||| IN
Michigan ||| S:807 E:815 ||| NNP
,  ||| S:815 E:817 ||| ,
CareFirst  ||| S:817 E:827 ||| JJ
BlueCross  ||| S:827 E:837 ||| JJ
BlueShield ||| S:837 E:847 ||| NN
,  ||| S:847 E:849 ||| ,
Empire  ||| S:849 E:856 ||| NNP
BlueCross  ||| S:856 E:866 ||| NNP
BlueShield ||| S:866 E:876 ||| NNP
,  ||| S:876 E:878 ||| ,
HealthNow ||| S:878 E:887 ||| NNP
,  ||| S:887 E:889 ||| ,
Humana ||| S:889 E:895 ||| NNP
,  ||| S:895 E:897 ||| ,
Independence  ||| S:897 E:910 ||| NNP
BlueCross ||| S:910 E:919 ||| NNP
,  ||| S:919 E:921 ||| ,
Priority  ||| S:921 E:930 ||| NNP
Health ||| S:930 E:936 ||| NNP
,  ||| S:936 E:938 ||| ,
and  ||| S:938 E:942 ||| CC
UnitedHealthcare ||| S:942 E:958 ||| JJ
.  ||| S:958 E:960 ||| .
Although  ||| S:960 E:969 ||| IN
this  ||| S:969 E:974 ||| DT
group  ||| S:974 E:980 ||| NN
is  ||| S:980 E:983 ||| VBZ
diverse ||| S:983 E:990 ||| JJ
,  ||| S:990 E:992 ||| ,
it  ||| S:992 E:995 ||| PRP
does  ||| S:995 E:1000 ||| VBZ
not  ||| S:1000 E:1004 ||| RB
constitute  ||| S:1004 E:1015 ||| VB
a  ||| S:1015 E:1017 ||| DT
representative  ||| S:1017 E:1032 ||| JJ
cross-section  ||| S:1032 E:1046 ||| NN
of  ||| S:1046 E:1049 ||| IN
MCOs  ||| S:1049 E:1054 ||| JJ
across  ||| S:1054 E:1061 ||| IN
the  ||| S:1061 E:1065 ||| DT
United  ||| S:1065 E:1072 ||| NNP
States ||| S:1072 E:1078 ||| NNPS
.  ||| S:1078 E:1080 ||| .
NCCN  ||| S:1080 E:1085 ||| NNP
interviewed  ||| S:1085 E:1097 ||| VBD
these  ||| S:1097 E:1103 ||| DT
executives  ||| S:1103 E:1114 ||| NNS
about  ||| S:1114 E:1120 ||| IN
the  ||| S:1120 E:1124 ||| DT
priority  ||| S:1124 E:1133 ||| NN
of  ||| S:1133 E:1136 ||| IN
cancer  ||| S:1136 E:1143 ||| NN
care  ||| S:1143 E:1148 ||| NN
management  ||| S:1148 E:1159 ||| NN
for  ||| S:1159 E:1163 ||| IN
their  ||| S:1163 E:1169 ||| PRP$
organizations  ||| S:1169 E:1183 ||| NNS
and  ||| S:1183 E:1187 ||| CC
the  ||| S:1187 E:1191 ||| DT
strategies  ||| S:1191 E:1202 ||| NNS
being  ||| S:1202 E:1208 ||| VBG
used  ||| S:1208 E:1213 ||| VBN
to  ||| S:1213 E:1216 ||| TO
address  ||| S:1216 E:1224 ||| VB
cost  ||| S:1224 E:1229 ||| NN
and  ||| S:1229 E:1233 ||| CC
quality  ||| S:1233 E:1241 ||| NN
of  ||| S:1241 E:1244 ||| IN
cancer  ||| S:1244 E:1251 ||| NN
care ||| S:1251 E:1255 ||| NN
.  ||| S:1255 E:1257 ||| .
The  ||| S:1257 E:1261 ||| DT
information  ||| S:1261 E:1273 ||| NN
garnered  ||| S:1273 E:1282 ||| NN
from  ||| S:1282 E:1287 ||| IN
these  ||| S:1287 E:1293 ||| DT
interviews  ||| S:1293 E:1304 ||| NNS
was  ||| S:1304 E:1308 ||| VBD
qualitative  ||| S:1308 E:1320 ||| VBN
in  ||| S:1320 E:1323 ||| IN
nature ||| S:1323 E:1329 ||| NN
.  ||| S:1329 E:1331 ||| .
A  ||| S:1331 E:1333 ||| DT
separate  ||| S:1333 E:1342 ||| JJ
quantitative  ||| S:1342 E:1355 ||| JJ
analysis  ||| S:1355 E:1364 ||| NN
of  ||| S:1364 E:1367 ||| IN
trends  ||| S:1367 E:1374 ||| NNS
in  ||| S:1374 E:1377 ||| IN
oncology  ||| S:1377 E:1386 ||| JJ
managed  ||| S:1386 E:1394 ||| JJ
care  ||| S:1394 E:1399 ||| NN
has  ||| S:1399 E:1403 ||| VBZ
already  ||| S:1403 E:1411 ||| RB
been  ||| S:1411 E:1416 ||| VBN
published ||| S:1416 E:1425 ||| VBN
,  ||| S:1425 E:1427 ||| ,
and  ||| S:1427 E:1431 ||| CC
throughout  ||| S:1431 E:1442 ||| IN
this  ||| S:1442 E:1447 ||| DT
report ||| S:1447 E:1453 ||| NN
,  ||| S:1453 E:1455 ||| ,
data  ||| S:1455 E:1460 ||| NNS
from  ||| S:1460 E:1465 ||| IN
the  ||| S:1465 E:1469 ||| DT
2009-2010  ||| S:1469 E:1479 ||| NNP
Genentech  ||| S:1479 E:1489 ||| NNP
Oncology  ||| S:1489 E:1498 ||| NNP
Trend  ||| S:1498 E:1504 ||| NNP
Report  ||| S:1504 E:1511 ||| NNP
are  ||| S:1511 E:1515 ||| VBP
referenced  ||| S:1515 E:1526 ||| VBN
to  ||| S:1526 E:1529 ||| TO
supplement  ||| S:1529 E:1540 ||| VB
findings  ||| S:1540 E:1549 ||| NNS
from  ||| S:1549 E:1554 ||| IN
the  ||| S:1554 E:1558 ||| DT
NCCN  ||| S:1558 E:1563 ||| NNP
interviews ||| S:1563 E:1573 ||| NNS
.  ||| S:1573 E:1575 ||| .
